Systemic Inflammation and Oxidative Stress in Adults with Bronchiectasis: Association with Clinical and Functional Features.

OBJECTIVES: To compare the inflammatory and oxidative stress (OS) states of adults with bronchiectasis with those of healthy controls and correlate inflammatory and OS levels with lung function and physical capacity. METHODS: This study used a cross-sectional design. Seventy-four adults with bronchiectasis (age: 49±15 years, forced expiratory volume in 1 second [FEV1]: 52.5±25.6%) and 42 healthy controls (age: 44±17 years, FEV1: 95.9±14.0%) performed cardiopulmonary exercise tests and incremental shuttle walking tests. Their physical activity in daily life, inflammatory cytokine, and antioxidant levels in plasma were measured. RESULTS: Compared to that of the controls, the levels of interleukin (IL)-6 (p<0.001), IL-10 (p<0.001), carbonylated proteins (p=0.001), and superoxide anions (p=0.046) were significantly increased in adults with bronchiectasis. Catalase activity was also reduced in this group (p<0.001). The inflammatory markers IL-1ß, IL-6, and tumor necrosis factor-α correlated negatively with aerobic capacity (r=-0.408, r=-0.308, and r=-0.207, respectively). We observed similar correlations with OS markers (thiobarbituric acid and carbonyls; r=-0.290 and r=0.379, respectively), and these markers also significantly correlated with the aerobic capacity. CONCLUSIONS: Adults with bronchiectasis presented an increased systemic inflammatory response that correlated negatively with physical capacity.

Systemic inflammation and oxidative stress in adults with bronchiectasis: association with clinical and functional features

OBJECTIVES: To compare the inflammatory and oxidative stress (OS) states of adults with bronchiectasis with those of healthy controls and correlate inflammatory and OS levels with lung function and physical capacity. METHODS: This study used a cross-sectional design. Seventy-four adults with bronchiectasis (age: 49±15 years, forced expiratory volume in 1 second [FEV1]: 52.5±25.6%) and 42 healthy controls (age: 44±17 years, FEV1: 95.9±14.0%) performed cardiopulmonary exercise tests and incremental shuttle walking tests. Their physical activity in daily life, inflammatory cytokine, and antioxidant levels in plasma were measured. RESULTS: Compared to that of the controls, the levels of interleukin (IL)-6 (p<0.001), IL-10 (p<0.001), carbonylated proteins (p=0.001), and superoxide anions (p=0.046) were significantly increased in adults with bronchiectasis. Catalase activity was also reduced in this group (p<0.001). The inflammatory markers IL-1β, IL-6, and tumor necrosis factor-α correlated negatively with aerobic capacity (r=-0.408, r=-0.308, and r=-0.207, respectively). We observed similar correlations with OS markers (thiobarbituric acid and carbonyls; r=-0.290 and r=0.379, respectively), and these markers also significantly correlated with the aerobic capacity. CONCLUSIONS: Adults with bronchiectasis presented an increased systemic inflammatory response that correlated negatively with physical capacity.

Incremental shuttle walk test performed in a hallway and on a treadmill: are they interchangeable? / Shuttle walk teste incremental realizado no corredor e na esteira: eles são intercambiáveis? / La prueba incremental Shuttle walk realizada en el pasillo y la cinta caminadora: ¿son intercambiables?

ABSTRACT The performances of healthy individuals in an incremental shuttle walking test performed in a hallway (ISWT-H) and on a treadmill (ISWT-T) were compared to assess their physiological responses during aerobic training sessions with the speeds estimated from both tests. This was a cross-sectional study with 55 healthy subjects, who were randomized to perform the ISWT tests with 24 hours between them. Training sessions were held using a treadmill at 75% of the speeds obtained from the ISWT-H and ISWT-T. Measurements included walking distance, oxygen uptake (VO2), carbon dioxide (VCO2) production, heart rate (HR), and ventilation (VE). There was a significant difference between walking distances (ISWT-T: 823.9±165.2 m and ISWT-H:685.4±141.4 m), but similar physiological responses for VO2 (28.6±6.6 vs. 29.0±7.3 ml-1.kg-1.min-1), VCO2 (1.9±0.7 vs. 1.9±0.5 1), HR (158.3±17.8 vs. 158.6±17.7 bpm), and VE (41.5±10.4 vs. 43.7±12.9 1). The estimated speeds were different for the training sessions (5.5±0.5 km/h and 4.9±0.3 km/h), as well as the VO2, VCO2, VE, and HR. It was concluded that in healthy young adults, ISWTs carried out in a hallway and on a treadmill are not interchangeable. Since the ISWT-H was determined to have lower speed, the training intensity based on this test may underestimate a patient's responses to aerobic training.

RESUMO Comparou-se o desempenho no shuttle walk teste incremental realizado no corredor (SWTI-C) e na esteira (SWTI-E) em indivíduos saudáveis e comparar as respostas fisiológicas durante as sessões de treinamento aeróbio com as velocidades estimadas em ambos os testes. Trata-se de um estudo transversal com cinquenta e cinco participantes saudáveis. Os participantes foram randomizados para realizar os testes com 24 horas de intervalo. As sessões de treinamento foram realizadas na esteira com 75% da velocidade obtida no SWTI-C e no SWTI-E. As avaliações incluíram a distância da caminhada, consumo de oxigênio (VO2), produção de dióxido de carbono (VCO2), frequência cardíaca (FC) e ventilação (VE). Houve uma diferença significante entre as distâncias caminhadas (SWTI-E: 823,9 ± 165,2 m e SWTI-C: 685,4 ± 141,4 m), mas respostas fisiológicas semelhantes para o VO2 (28,6 ± 6,6 vs. 29,0 ± 7,3 ml-1.kg-1.min-1), VCO2 (1,9 ± 0,7 vs. 1,9 ± 0,5 1), HR (158,3 ± 17,8 vs. 158,6 ± 17,7 bpm) e VE (41,5 ± 10,4 vs. 43,7 ± 12,9 1). As velocidades estimadas foram diferentes para as sessões de treinamento (5,5 ± 0,5xkm/h e 4,9 ± 0,3 km/h), assim como o VO2, VCO2, VE e FC. Concluiu-se que em adultos jovens saudáveis, SWTI realizados no corredor e na esteira não são intercambiáveis. Uma vez que o SWTI-E determinou uma menor velocidade, a intensidade do treinamento baseada neste teste pode subestimar as respostas de um paciente ao treinamento aeróbio.

RESUMEN Se trata de una comparación del rendimiento en la prueba incremental shuttle walk llevado a cabo en el pasillo (SWPI-P) y en la cinta caminadora (SWPC) entre individuos sanos, para evaluar las respuestas fisiológicas durante las sesiones de entrenamiento aeróbico con velocidades estimadas en ambas pruebas. Estudio transversal con 55 individuos sanos. A los participantes se les eligieron al azar para realizar las pruebas con intervalo de 24 horas. Se llevaron a cabo sesiones de entrenamiento en la cinta caminadora con el 75 % de la velocidad obtenida en SWPI-P y en SWPC. Se incluyen entre las evaluaciones la distancia de la caminata, el consumo de oxígeno (VO2), la producción de dióxido de carbono (VCO2), la frecuencia cardiaca (FC) y la ventilación (VE). Hubo una diferencia significativa entre las distancias recorridas (SWPC: 823,9 ± 165,2 m y SWPI-P: 685,4 ± 141,4 m), pero similares a las respuestas fisiológicas del VO2 (28,6 ± 6,6 vs. 29,0 ± 7,3 ml-1.kg-1. min-1), VCO2 (1,9 ± 0,7 vs. ± 1,9 0,5 1), HR (158,3 ± 17,8 vs. 158,6 ± 17,7 bpm) y VE (41,5 ± 10,4 vs. 43,7 ± 12,9 1). Las velocidades estimadas fueron diferentes en las sesiones de entrenamiento (5,5 ± 0,5 km/h y 4,9 ± 0,3 km/h), así como VO2, VCO2, VE y FC. Se concluyó que, en los adultos jóvenes sanos, la SWPI llevada a cabo en el pasillo y en la cinta caminadora no pueden ser intercambiables. Dado que la SWPC determinó una menor velocidad, la intensidad de entrenamiento de esta prueba puede subestimar las respuestas de un paciente en el entrenamiento aeróbico.

Reduced Physical Activity With Bronchiectasis.

BACKGROUND: Bronchiectasis leads to reduced functional capacity, which might have implications for physical activity. The impact of dyspnea and long-term oxygen therapy on physical activity has never been investigated in subjects with bronchiectasis. Based on these findings, specific strategies could be applied to allow individuals to be more active in their daily life. In this study we aimed to evaluate physical activity, the impact of dyspnea and long-term oxygen therapy on physical activity, and the determinants of physical activity in subjects with bronchiectasis. METHODS: We performed a cross-sectional study in 139 subjects with bronchiectasis (age 45 ± 13 y, FVC 70 ± 22% of predicted, FEV1 54 ± 25% of predicted) and 49 healthy subjects as controls. Physical activity was assessed using steps per day (measured with a pedometer), spirometry, incremental shuttle walking test (ISWT), and dyspnea. RESULTS: Reduced physical activity was observed in subjects with bronchiectasis, who recorded a median (interquartile range) of 8,007 (5,131-10,432) steps/d compared with controls, who recorded 10,994 (8,551-14,078) steps/d (P < .001). Significant correlations were observed between physical activity and FVC (r = 0.43), FEV1 (r = 0.36), ISWT (r = 0.37), and dyspnea (r = -0.48). Determinants for reduced physical activity included pulmonary function (R2 = 0.150), dyspnea (R2 = 0.075), ISWT (R2 = 0.044), and long-term oxygen therapy (R2 = 0.038); these factors explained 32% of the physical activity. CONCLUSION: Subjects with bronchiectasis exhibited reduced physical activity compared with healthy peers. Dyspnea has a negative impact on physical activity. Independent factors associated with physical activity included pulmonary function, dyspnea, functional capacity, and long-term oxygen therapy. These findings will guide strategies to enhance daily physical activity and to encourage subjects with bronchiectasis to be more active.

Effects of a pulmonary rehabilitation program on physical capacity, peripheral muscle function and inflammatory markers in asthmatic children and adolescents: study protocol for a randomized controlled trial.

BACKGROUND: Individuals with chronic lung disease are more susceptible to present reduction in exercise tolerance and muscles strength not only due to pulmonary limitations but also due systemic repercussions of the pulmonary disease. The aim of this study is to assess the physical capacity, peripheral muscle function, physical activity in daily life, and the inflammatory markers in children and adolescents with asthma after pulmonary rehabilitation program. METHOD: This is a study protocol of randomized controlled trial in asthmatic patients between 6 to 18 years old. The assessments will be conducted in three different days and will be performed at the beginning and at the end of the protocol. First visit: quality of life questionnaire, asthma control questionnaire, pre- and post-bronchodilator spirometry (400 µcg salbutamol), inflammatory assessment (blood collection), and cardiopulmonary exercise test on a cycle ergometer to determine aerobic capacity. Second visit: assessment of strength and endurance of the quadriceps femoris and biceps brachii muscles with concomitant electromyography to assess peripheral muscle strength. Third visit: incremental shuttle walk test (ISWT) and accelerometer to evaluate functional capacity and physical activity in daily life during 7 days. Then, the volunteers will be randomized to receive pulmonary rehabilitation program (intervention group) or chest physiotherapy + stretching exercises (control group). Both groups will have a supervised session, twice a week, each session will have 60 minutes duration, with minimum interval of 24 hours, for a period of 8 weeks. Intervention group: aerobic training (35 minutes) intensity between 60 to 80 % of the maximum workload of cardiopulmonary exercise testing or of ISWT; strength muscle training will be applied to the quadriceps femoris, biceps brachii and deltoid muscles (intensity: 40 to 70 % of maximal repetition, 3 x 8 repetition); finally the oral high-frequency oscillation device (Flutter®) will be used for 5 minutes. The control group: oral high-frequency oscillation device (Flutter®) for 10 minutes followed by the stretching of upper and lower limbs for 40 minutes. It is expected to observe the improvement in aerobic capacity, physical activity in daily life, muscle strength and quality of life of patients in the intervention group, and reduction in inflammatory markers. CLINICAL TRIAL NUMBER: NCT02383069. Data of registration: 03/03/2015.